The 1H 2018 Result Nuts and Bolts, page-7

From Motley F.

3 healthcare shares every investor should read up on

Nanosonics Ltd (ASX: NAN)
Infection prevention is front and centre across the globe at the moment as superbug stories send entire continents reaching for their face masks.

Involved in the manufacturing and distribution of the trophon EPR ultrasound probe disinfector, Nanosonics received some flak for its recent interim result, with revenue down 17% and a 64% drop in pre-tax profit from the previous corresponding period.

But despite the dramatic headlines, there was still plenty of good to be found in the results, with the company poised for strong growth in trophon EPR sales globally, with another infection prevention solution product in the works due to strong demand from the sector
.
If Nanosonic’s future products are as successful as their current, growth looks likely and any share price slide off the back of unfavourable results may pave the way for a buying opportunity as Nanosonic shares sit at $2.71 at the time of writing, down from its pre-results release price of $2.98 on February 21.